Provision of Antioxidant Therapy in Hemodialysis (PATH) Study

Completed · Phase 2 · Has a placebo group

Conditions studied: End-stage Renal Disease

In brief

Studies have shown that end stage renal disease (ESRD) patients have higher levels of blood markers which their body makes in response to increased stress and injury. An increase in these markers have been shown to be related to cardiovascular disease and death in ESRD patients. This study will examine whether antioxidant therapy (Vitamin E and alpha lipoic acid) may decrease these markers.

Key facts

Study ID
NCT00237718
Run by
Vanderbilt University
People needed
385
Starts
2006-04-01
Expected to finish
2010-09-01
Last updated by the study team
2012-01-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.